Astellas Unveils New Findings on XOSPATA at ASH 2025, Signifying Hope for AML Patients Astellas Pharma Inc. will showcase new research on XOSPATA™ at the ASH 2025 Annual Meeting, focusing on treatment strategies for FLT3m+ AML patients and outcomes in relapsed cases.

Astellas Unveils New Findings on XOSPATA at ASH 2025, Signifying Hope for AML Patients #XOSPATA #gilteritinib #FLT3m+_AML